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Cardiovascular disease is the commonest 
cause of mortality in Australia, accounting for 
more than 30% of deaths.1 Hypertension, 
diabetes and lipid disorders account for 
15.6% of the total problems encountered in 
general practice.2 Therefore all doctors should 
be familiar with well known risk factors for 
cardiovascular disease, as well as the benefits 
of interventions with them.3 There are a 
number of absolute risk calculators available 
such as the New Zealand Cardiovascular 
Risk Calculator (www.nps.org.au/docs/pdfs/
cardiovascularrisk.pdf) and the Framingham 
Heart Study Prediction Score Sheets (www.
nhlbi.nih.gov/about/framingham/riskabs.
htm). There are also numerous guidelines on 
management,4–7 but these usually focus on 
single interventions and are liable to become 
outdated as new evidence emerges. 
Method
A multidisciplinary group of physicians 
formulated a concise and up-to-date guide for 
the prevention of cardiovascular disease based 
on a rigorous analysis of the available published 
evidence.3 This information was condensed 
into a single page desktop chart for clinical use. 
Between July and October 2001, five meetings 
organised by a pharmaceutical company were 
held in Sydney, Brisbane, Adelaide, Melbourne 
and Perth. The meetings were about risk 
factors and management of cardiovascular 
disease to which general practitioners were 
sent postal invitations. They lasted 2 hours, 
attracted quality assurance and continuing 
medical education points from The Royal 
Australian College of General Practitioners 
and were chaired by a local GP. They took the 
form of two interactive presentations from a 
local cardiologist and GP academic, followed 
by questions and discussion, and ended with 
supper. During the course of the meeting, 
GPs were provided with the evidence based 
clinical aid. 
 Participants were asked to complete an 
18 item questionnaire seeking their views on 
evidence based medicine (EBM) in general, and 
on the clinical aid in particular. This feedback 
guided the final development of the aid that 
was published 2 years later.3 
Results
Out of 335 questionnaires distributed, 259 were 
completed (77% response rate). The responding 
GPs were more likely than those participating in 
the Bettering the Evaluation and Care of Health 
(BEACH) program in 2001–2002 to be male and 
in solo or small practices (Table 1). 
 When asked the sources used to access 
the latest EBM; 75% cited clinical journals, 
58% pharmaceutical company representatives, 
42% clinical meetings, and 22% cited the 
internet. Asked about the relevance of EBM, 
82% stated it was difficult to be continuously 
up-to-date with the latest evidence, 69% 
wanted to be aware of the evidence; but 
only 29% believed it was the basis for ‘gold 
standard’ clinical practice. 
 The evidence based clinical aid was 
thought appropriate and relevant to practice 
by 77%, although 39% suggested changes. 
These included having some linkage to a 
computerised format (71%), simplifying the 
text and layout (45%), and providing more 
explanation (8%). When asked the best 
way for GP colleagues to be introduced to 
the clinical aid, 53% identified small workshops, 
44% meetings such as they were attending, 
and 28% identified divisions of general practice.
Discussion
Our primary aim was to provide a summary 
of the evidence for cardiovascular disease 
in a user friendly format according to the 
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best principles. But it also allowed for the 
evaluation of the format. The convenience 
sampling means these opinions may not be 
representative of Australian GPs. Despite the 
over-representation of male GPs, and those 
from solo and small practices – which probably 
reflects their educational preferences – the 
relatively positive opinions on the relevance 
of EBM are encouraging. Other studies have 
demonstrated less positive attitudes to EBM 
among solo GPs.9 
 Positive attitudes to clinical practice 
guidelines and EBM10–16 may not translate to 
changes in clinical practice.17,18 Our finding that 
less than one-third of respondents believed 
that EBM was the basis for ‘gold standard’ 
clinical practice may be the consequence of 
scepticism and pessimism about the value 
of clinical practice guidelines previously 
described.10–13,17,18 
 For more than half the GPs, access to the 
latest evidence was from pharmaceutical 
company representatives (the second most 
popular source). As the meetings were 
organised by a pharmaceutical company this 
may indicate social response bias. Nonetheless, 
this may reflect a considerable influence of the 
pharmaceutical industry (of particular concern 
if there are strong interactions between 
clinical practice guideline authors and the 
pharmaceutical industry).19 
 The strong support for having some linkage 
to a computerised format, and the preference 
for small workshops and educational meetings 
as dissemination mechanisms should provide 
useful pointers for guideline developers, policy 
makers and health service managers. 
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• Ou t  o f  259  GPs  su r veyed  a t 
pharmaceutical company sponsored 
educational meetings on cardiovascular 
disease guidelines: 
 –  75% said they used journals as a 
source of evidence 
 –  58% pharmaceutical representatives 
 –  42% clinical meetings, and 
 –  22% used the internet.
• Many felt positive about EBM and 
decision aids, although 82% thought 
it was difficult to maintain being up-to-
date with the latest evidence.
• Only 29% thought EBM was a basis for 
gold standard clinical practice.
• GPs thought  be ing engaged in 
developing decision support tools 
before dissemination should increase 
acceptability and uptake.





Table 1. Characteristics of the GPs responding compared with those 
participating in the BEACH program8
Characteristics Respondents (%)  95% confidence  GPs participating 
 (n=259) limits in BEACH (%) 
   (n=1000)  
Sex
Male 80 (75.1 – 84.9) 64 
Female 20 (15.1 – 24.9) 36 
Age range
<35 7 (3.5 – 9.5) 7
35–44 23 (17.9 – 28.1) 27
45–54 42 (35.5 – 47.5) 37
55+ 29 (23.5 – 34.5) 30
Practice size
Solo 27 (21.4 – 32.2) 15
2–4 46 (39.4 – 51.6) 40
5+ 28 (22.2 – 33.0) 45
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